BBIO Projected Dividend Yield
BridgeBio Pharma Inc ( NASDAQ : BBIO )BridgeBio Pharma is a biopharmaceutical company to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. Co.'s pipeline includes: Acoramidis (Eidos), which is an oral small molecule Transthyretin (TTR) stabilizer for the treatment of TTR amyloidosis; Low-dose Infigratinib, which is an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of achondroplasia; BBP-418, which is a small molecule substrate replacement therapy for the treatment of Limb Girdle Muscular Dystrophy Type 2I; and BBP-812, which is an adeno-associated virus gene therapy for the treatment of Canavan Disease. 20 YEAR PERFORMANCE RESULTS |
BBIO Dividend History Detail BBIO Dividend News BBIO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |